169 related articles for article (PubMed ID: 37820599)
21. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
Guo W; Zheng Y; Feng S
Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics.
Innocenti I; Tomasso A; Benintende G; Autore F; Fresa A; Vuono F; Stirparo L; Galli E; D'Arena G; Sorà F; Efremov D; Laurenti L
Hematol Oncol; 2022 Aug; 40(3):469-474. PubMed ID: 35076123
[TBL] [Abstract][Full Text] [Related]
23. Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.
Ujjani C; Gooley TA; Spurgeon SE; Stephens DM; Lai C; Broome CM; O'Brien S; Zhu H; Laing KJ; Winter AM; Pongas G; Greninger AL; Koelle DM; Siddiqi T; Davids MS; Rogers KA; Danilov AV; Sperling A; Tu B; Sorensen T; Launchbury K; Burrow CJ; Quezada G; Hill JA; Shadman M; Thompson PA
Blood Adv; 2023 Sep; 7(17):4728-4737. PubMed ID: 36516082
[TBL] [Abstract][Full Text] [Related]
24. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.
Randhawa JK; Ferrajoli A
Expert Rev Hematol; 2016 Mar; 9(3):235-44. PubMed ID: 26652692
[TBL] [Abstract][Full Text] [Related]
25. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Chatzikonstantinou T; Kapetanakis A; Scarfò L; Karakatsoulis G; Allsup D; Cabrero AA; Andres M; Antic D; Baile M; Baliakas P; Bron D; Capasso A; Chatzileontiadou S; Cordoba R; Correa JG; Cuéllar-García C; De Paoli L; De Paolis MR; Del Poeta G; Demosthenous C; Dimou M; Donaldson D; Doubek M; Efstathopoulou M; Eichhorst B; El-Ashwah S; Enrico A; Espinet B; Farina L; Ferrari A; Foglietta M; Frederiksen H; Fürstenau M; García-Marco JA; García-Serra R; Gentile M; Gimeno E; Glenthøj A; Gomes da Silva M; Gutwein O; Hakobyan YK; Herishanu Y; Hernández-Rivas JÁ; Herold T; Innocenti I; Itchaki G; Jaksic O; Janssens A; Kalashnikova ОB; Kalicińska E; Karlsson LK; Kater AP; Kersting S; Labrador J; Lad D; Laurenti L; Levin MD; Lista E; Lopez-Garcia A; Malerba L; Marasca R; Marchetti M; Marquet J; Mattsson M; Mauro FR; Milosevic I; Mirás F; Morawska M; Motta M; Munir T; Murru R; Niemann CU; Rodrigues RN; Olivieri J; Orsucci L; Papaioannou M; Pavlovsky MA; Piskunova I; Popov VM; Quaglia FM; Quaresmini G; Qvist K; Reda G; Rigolin GM; Ruchlemer R; Saghumyan G; Shrestha A; Šimkovič M; Špaček M; Sportoletti P; Stanca O; Stavroyianni N; Tadmor T; Te Raa D; Tonino SH; Trentin L; Van Der Spek E; van Gelder M; van Kampen R; Varettoni M; Visentin A; Vitale C; Wasik-Szczepanek E; Wróbel T; San Segundo LY; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Stamatopoulos K; Ghia P
Leukemia; 2021 Dec; 35(12):3444-3454. PubMed ID: 34725454
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Kochneva ОL; Kislova M; Zhelnova EI; Petrenko AA; Baryakh EA; Yatskov KV; Dmitrieva EA; Misurina EN; Nikitin KE; Vasilieva EJ; Samsonova IV; Ptushkin VV; Baranova A; Nikitin EA
Leuk Lymphoma; 2022 Jul; 63(7):1607-1616. PubMed ID: 35156528
[TBL] [Abstract][Full Text] [Related]
27. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
[TBL] [Abstract][Full Text] [Related]
28. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
29. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM; Koff JL; Blum KA; Ayers AA; O'Leary CB; Churnetski MC; Sulaiman S; Kives M; Sheng P; Davis CW; Nooka AK; Antia R; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
J Clin Oncol; 2022 Sep; 40(26):3020-3031. PubMed ID: 35436146
[TBL] [Abstract][Full Text] [Related]
30. Timing of BNT162b2 vaccine prior to COVID-19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study.
Gutwein O; Herzog Tzarfati K; Apel A; Rahimi-Levene N; Ilana L; Tadmor T; Koren-Michowitz M
Cancer Med; 2023 Nov; 12(21):20503-20510. PubMed ID: 37877352
[TBL] [Abstract][Full Text] [Related]
31. Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.
Benjamini O; Gershon R; Bar-Haim E; Lustig Y; Cohen H; Doolman R; Kedmi M; Ribakovsky E; Kneller A; Hod T; Erez N; Levy I; Rahav G; Avigdor A
Eur J Haematol; 2023 Jan; 110(1):99-108. PubMed ID: 36208015
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
[TBL] [Abstract][Full Text] [Related]
33. Immune Dysfunction and Infection - Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs.
Gargiulo E; Teglgaard RS; Faitová T; Niemann CU
Acta Haematol; 2024; 147(1):84-98. PubMed ID: 37497921
[TBL] [Abstract][Full Text] [Related]
34. Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review.
Grywalska E; Zaborek M; Łyczba J; Hrynkiewicz R; Bębnowska D; Becht R; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Góźdź S; Roliński J; Niedźwiedzka-Rystwej P
Cells; 2020 Nov; 9(11):. PubMed ID: 33147729
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.
Langerbeins P; Fürstenau M; Gruell H; Klein F; Persigehl T; Rybniker J; Seeger-Nukpezah T; Kochanek M; Hallek M; Eichhorst B; Koehler P; Böll B
Eur J Haematol; 2020 Oct; 105(4):508-511. PubMed ID: 32575156
[TBL] [Abstract][Full Text] [Related]
36. Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?
Dreger P
Cancer J; 2021 Jul-Aug 01; 27(4):297-305. PubMed ID: 34398556
[TBL] [Abstract][Full Text] [Related]
37. Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
Doukas PG; St Pierre F; Karmali R; Mi X; Boyer J; Nieves M; Ison MG; Winter JN; Gordon LI; Ma S
Oncologist; 2023 Oct; 28(10):e930-e941. PubMed ID: 37141401
[TBL] [Abstract][Full Text] [Related]
38. Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
Zaleska J; Kwasnik P; Paziewska M; Purkot J; Szabelak A; Jurek M; Masny N; Dziatkiewicz I; Pronobis-Szczylik B; Piebiak A; Szymczyk A; Jarosz-Chudzik K; Bolkun L; Kozlowska K; Piszcz J; Subocz E; Halka J; Bator M; Kalicinska E; Wrobel T; Usnarska-Zubkiewicz L; Rybka J; Deren-Wagemann I; Szyca-Smieszniak M; Dybko J; Hus I; Pula B; Cichocka E; Rymko M; Zdunczyk D; Ziarkiewicz M; Basak GW; Bullinger L; Giannopoulos K
Int J Cancer; 2023 Feb; 152(4):705-712. PubMed ID: 35830214
[TBL] [Abstract][Full Text] [Related]
39. Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies.
Rivera D; Ferrajoli A
Curr Oncol Rep; 2022 Aug; 24(8):1003-1014. PubMed ID: 35366167
[TBL] [Abstract][Full Text] [Related]
40. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia.
Tadmor T; Welslau M; Hus I
Expert Rev Hematol; 2018 Jan; 11(1):57-70. PubMed ID: 29160119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
